Posted in | News | Chemical Sensor

PositiveID Achieves Major Development Milestone in Glucose-Sensing RFID Microchip

PositiveID has declared that it has achieved a significant landmark in developing its GlucoChip, a RFID microchip that senses glucose levels. The company has built reverse anchor and anchor building blocks and also competitor constructs that are capable of attaching with glucose for producing direct and repeatable interpretation of glucose levels.

Both the building blocks and the competitor constructs can be incorporated in the glucose sensor. The company is looking forward to improve the glucose sensing system by the middle of 2011, and will shortly include the sensing system with the RFID microchip electronics to finalize the development of the glucose sensor.

Currently, the company is in the second phase of GlucoChip development. The Phase II is focused on enhancing the sensing system for its response to glucose and showing the incorporation of the parts into a steady and repeatable glucose sensing system, which will be glucose sensor’s critical component. The company monitored the binding of anchor and reverse anchor constructs with glucose and also the aptness for immobilizing on a rigid surface. The outcomes of the testing will enable the selection of ideal glucose binding pairs that can be included in the archetype.

The President and Chief Science Officer at Receptors, PositiveID's Development Partner, Robert E. Carlson stated that the accomplishment has given them more confidence for developing a reliable and repeatable glucose sensing system. He added that building a material that can attach to glucose and develop a constant response curve, which can be interpreted and compared to glucose levels, was a major task for them.

The Chairman and CEO of PositiveID, Scott R. Silverman mentioned that they are determined to take the GlucoChip to the next development phase by using their proficiency with implantable RFID microchips.

PositiveID is working with Receptors to develop the GlucoChip. The glucose-sensing microchip is developed based on VeriChip, Positive ID’s FDA certified microchip used for patient recognition and is also based on the Embedded Bio-Sensor System with Positive ID’s Patent No. 7,125,382. The Embedded Bio-Sensor System uses radio frequency recognition technology and features a remote transponder that can wirelessly interact with an implantable on-chip transponder.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Choi, Andy. (2019, February 24). PositiveID Achieves Major Development Milestone in Glucose-Sensing RFID Microchip. AZoSensors. Retrieved on November 21, 2024 from https://www.azosensors.com/news.aspx?newsID=2373.

  • MLA

    Choi, Andy. "PositiveID Achieves Major Development Milestone in Glucose-Sensing RFID Microchip". AZoSensors. 21 November 2024. <https://www.azosensors.com/news.aspx?newsID=2373>.

  • Chicago

    Choi, Andy. "PositiveID Achieves Major Development Milestone in Glucose-Sensing RFID Microchip". AZoSensors. https://www.azosensors.com/news.aspx?newsID=2373. (accessed November 21, 2024).

  • Harvard

    Choi, Andy. 2019. PositiveID Achieves Major Development Milestone in Glucose-Sensing RFID Microchip. AZoSensors, viewed 21 November 2024, https://www.azosensors.com/news.aspx?newsID=2373.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.